NEO: Financial results · Leadership change

Item 2.02 Results of Operations and Financial Condition. On October 5, 2026, NeoGenomics, Inc. (the “ Company ”) issued a press release that included certain preliminary financial results as of and for the quarter ended September 30, 2026. The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 5.02 Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. CEO Transition On September 30, 2026, the Board of Directors (the “ Board ”) of the Company approved the appointment of Warren Stone, the Company’s current President and Chief Operating Officer, as Chief Executive Officer of the Company and a member of the Board, effective as of January 4, 2027. In connection with Mr. Stone’s appointment as Chief Executive Officer, on September 30, 2026, the Board also approved the executive transition of Tony Zook, the Company’s current Chief Executive Officer and a member of the Board, to the role of Executive Chairman, effective as of January 4, 2027. Mr. Stone, 54, joined the Company in November 2022 as the Company’s President, Clinical Services, was appointed as Chief Commercial Officer in April 2024 and was appointed President